In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer. We dived deep into the most impactful studies, including: • MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings.• Metastatic HR+ Disease: Insights on the latest data surrounding PIK3CA mutations, with results from the VIKTORIA1 trial with Gedatolisib, and evERA study with Giredestrant. • HER2+ Breast Cancer: A comprehensive look at the DESTINY trials, highlighting the efficacy of Trastuzumab Deruxtecan (TDXd) in both neoadjuvant, adjuvant and palliative settings.• Triple Negative Breast Cancer: The role of sacituzumab and Dato-DXd in the first-line treatment landscape. Join us as we unpack these complex studies, discuss clinical implications, and share practical insights for community oncologists. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #ESMO2025 #BreastCancer #MonarchE #NATALEE #DESTINYtrials #CDK4/6 #ADCs #OncologyBrothers